REPRIEVE Substudy: Pitavastatin reduces non-calcified coronary plaque in people with HIV
Key Points The REPRIEVE trial recently demonstrated that pitavastatin reduced major adverse cardiovascular events by 35% among individuals with HIV at low-moderate risk predicted risk for cardiovascular disease. However, little…
NOAH-AFNET 6: AHRE>24 hours associated with low stroke risk but more likely to develop AF later
Key Points This pre-specific subanalysis of NOAH-AFNET 6 found that those with long lasting atrial high rate episodes >24 hours were more likely to develop atrial fibrillation (AF); there was…
ARTESIA: Apixaban reduces the risk of stroke in subclinical AF, with an increase in major non-fatal bleeding
Key Points This randomized trial of 4012 patients (median age ~77, mean CHA2DS2VASC ~4, ~65% male) with an implanted pacemaker, defibrillator, or cardiac monitor with subclinical atrial fibrillation (SCAF) found…
Novel siRNA targeting therapy lepodisiran results in a dose-dependent and sustained reduction in Lipoprotein(a)
Key Points: There are currently no approved targeted therapies for the reduction of Lp(a). In this Phase I study, a novel siRNA therapy (lepodisiran) was tested in escalating doses and…
ARIES-HM3: Aspirin avoidance Is safe and reduces bleeding events in patients with HM3 LVAD on VKA
Key Points: Since the advent of novel HeartMate 3 LVAD technology with lower thrombotic risk, the clinical utility of continuing to add aspirin to the antithrombotic strategy has not been…
POCKET-COST-HF: Comprehensive Cost Disclosure improves cost-informed decision making
Key Points: Out-of-pocket costs for GDMT in HFrEF have risen substantially with the advent of novel effective therapies. However, there is limited information regarding the utility of comprehensive cost disclosure…
Dietary sodium reduction significantly lowered BP in middle-aged to elderly adults
Key Points: Daily sodium intake remains high (on average ~3,500 mg/day), despite recommendations from the AHA and WHO to limit sodium intake to around 2,000 mg/day. Salt-sensitivity to BP (SSBP)…
TEAMMATE Trial: Everolimus with Low-Dose Tacrolimus to Prevent Rejection in Children after Cardiac Transplantation
Key Points This was the first randomized trial to evaluate the safety and efficacy of everolimus and low-dose tacrolimus in pediatric heart transplant recipients. The open-label trial demonstrated that this…
Percutaneous Coronary Intervention Improved Symptoms in Stable Angina: ORBITA-2 trial
Key points: PCI is often performed for chronic stable angina, but current evidence is unclear to what extent the benefit is physiologic vs placebo This trial compared PCI with placebo-procedure…
Lowering blood pressure significantly reduced dementia risk in people with hypertension in rural China
Key Points: Intensive blood pressure (BP) lowering intervention was tested on hypertensive patients in rural China. In this four year blood pressure intervention program in rural China, the intervention, led…
MINT Trial – In Patients with MI and Anemia, Liberal Blood Transfusion not Significantly Different to Restrictive Strategy in Reducing Death or MI
Key Points Anemia is common among individuals with acute myocardial infarction, however, transfusion thresholds and targets remain uncertain. The MINT trial randomized 3,506 patients with acute myocardial and anemia (hemoglobin…
DAPA-MI: Dapagliflozin improves clinical and cardiometabolic outcomes in post-AMI patients with impaired LV function versus placebo
Key Points This trial of patients with acute myocardial infarction (AMI) and impaired left ventricular (LV) systolic function found that dapagliflozin significantly improved clinical and cardiometabolic outcomes compared with placebo. …
SELECT TRIAL: Semaglutide reduces cardiovascular events among overweight or obese patients with cardiovascular disease in the absence of diabetes
Key Points: Semaglutide, a glucagon-like peptide-1 (GLP-1) analogue, has previously been shown to reduce body weight among overweight or obese individuals. However, data on whether the medication reduces cardiovascular events…
ARAMIS: Anakinra is safe but does not reduce complications of acute myocarditis
Key Points: While myocarditis is an inflammatory condition, there have not yet been trials demonstrating the benefit of anti-inflammatory therapies in the treatment of acute myocarditis. In the ARAMIS study,…
PUSH-AHF: Natriuresis-guided diuresis approach increases natriuresis and diuresis without improving all-cause mortality or HF hospitalization
Key Points: Diuretic requirement Is a major contributor to hospital length-of-stay for HF admissions, but the optimal strategy of diuretic optimization has not yet been established. Spot urinary sodium measurement…
SGLT2 inhibitors not linked with improved survival in hospitalized COVID-19 patients
Key Points: In hospitalized COVID-19 patients, treatments targeting the virus’s pathobiology (e.g. dysregulated immune response, inflammation, etc.) has been shown to improve outcomes Sodium glucose co-transporter 2 (SGLT2) inhibitors affect…
Inorganic nitrate improves safety of coronary angiography in patients at kidney injury risk
Key Points: Contrast-induced nephropathy (CIN) is a clinical condition that refers a deterioration in kidney function after contrast exposure and is a known complication of coronary angiography Some studies suggest…
Atrial Fibrillation ablation improves outcomes in patients with end-stage HF
Key Points Evidence suggests that catheter ablation for atrial fibrillation (AF) is associated with improved cardiovascular outcomes compared to medical therapy in patients with heart failure (HF). However, its use…
DICTATE-AHF Trial: Early Dapagliflozin in AHF does not meet primary endpoint of diuretic efficiency
Key Points: The DICTATE-AHF trial explored early initiation of the SGLT2 inhibitor dapagliflozin in acute decompensated heart failure (ADHF) patients. The trial did not show a statistically significant improvement in…
DANPACE II: Minimizing atrial pacing in sinus node dysfunction leads to increased syncope with no difference in development of AF
Key Points This trial randomizing patients with an indication for initial dual chamber (DDD) permanent pacemaker implantation (PPI) for sinus node dysfunction (SND) to a base rate of 60 beats…